Biotech | April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
The two-day event will showcase achievements and address issues pertaining to the industry
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Supply increase to help meet growing global demand
It aims to make the state-of-the-art modern and safe surgical care, typically available in super-speciality hospitals of big cities, accessible, affordable, standardized and integrated
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
The company inaugurated the new production line at the Bengaluru facility to manufacture Computed Tomography Scanners
Subscribe To Our Newsletter & Stay Updated
